Article Text

Download PDFPDF
P78 Robot-assisted management of endometrial cancer in belgium: an analysis of 615 patients by the belgian and luxembourg gynaecological oncology group
  1. S Ongaro1,
  2. C Ver Eecke2,
  3. F Peeters3,
  4. K Traen4,
  5. P Van Trappen5,
  6. A Kakkos1,
  7. A Laenen2,
  8. E Despierre4,
  9. E Van Nieuwenhuysen2,
  10. T Van Gorp2,
  11. F Kridelka1,
  12. I Vergote2 and
  13. F Goffin1
  1. 1Department of Obstetrics and Gynaecology, Centre Hospitalier Université de Liège, Site Notre Dame des Bruyères et Centre Hospitalier Régional Liège, Université de Liège, Liège
  2. 2Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, Leuven Cancer Institute, Catholic University of Leuven, Leuven
  3. 3Department of Obstetrics and Gynaecology, General Hospital Klina, Brasschaat
  4. 4Department of Obstetrics and Gynaecology, Onze-Lieve-Vrouwziekenhuis, Aalst
  5. 5Department of Obstetrics and Gynaecology, General Hospital Sint-Jan, Bruges, Belgium


Introduction/Background The aim of this prospective study was to report perioperative outcomes, disease-free and overall survival of robot-assisted management of patients with endometrial cancer, treated in 5 centers in Belgium.

Methodology Patients undergoing surgery between August 2007 and December 2018 (n=615) were prospectively collected.

Results Median age was 68 years (range, 31–92), median BMI 28 kg/m2 (range, 17–61). Five-hundred-ninety-nine patients underwent robot-assisted hysterectomy and bilateral salpingo-oophorectomy. In addition, full pelvic lymphadenectomy was performed in 151 (25%), and pelvic sentinel nodes biopsies only in 181 patients (29%). Sixteen patients were referred for robotic node staging after hysterectomy performed elsewhere. Histological types were endometrioid (n=512, 84%), serous (n=43, 7%), clear cell (n=8, 1%), mucinous (n=3, 0.5%), squamous (n=2, 0.3%) and carcinosarcoma (n=20, 3%). FIGO stage was: IA (61%), IB (24%), II (4%), IIIA (2%), IIIB (0,3%), IIIC (8%), IV (1%). Metastatic pelvic nodes were found in 43 (7%), positive para-aortic nodes in 3 (0,4%), pelvic and para-aortic nodal metastases in 7 patients (1,2%). Median number of removed pelvic and para-aortic nodes was 15 (range, 0–64) and 10 (range 1–47), respectively. Median estimated blood loss was 50 mL (range 0– 1000), median skin-to-skin time 150 minutes (range 55–480) and conversion rate 0.8% (n=5). Intra-operative complications occurred in 5% (n=30). At least one postoperative complication occurred in 15% (n=89). Median follow-up was 27 months (range, 1–131). Recurrence occurred in 63 patients (11%) and 38 patients (6%) died of endometrial cancer. The 2- and 5-year recurrence-free survival rates were 89% and 84%, respectively. The 2- and 5-year overall survival rates were 92% and 83%, respectively.

Conclusion This study confirms the feasibility and safety of robot-assisted management of endometrial cancer with a low complication, conversion and recurrence rate.

Disclosure Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.